Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017


19.06.17 15:30
Meldung
 
Helén Tuvesson new CEO of <strong>Active Biotech</strong> AB from July 1, 2017

PRESS RELEASE

Lund - Active Biotech AB (Nasdaq Stockholm: ACTI) today announces that the Board has appointed the company's current CSO Helén Tuvesson as new CEO of Active Biotech AB. Helén Tuvesson will take up the position on July 1, 2017, replacing Tomas Leanderson, who has been the company's CEO since 2008.



Helén Tuvesson has a broad experience in drug development after more than 20 years in the pharmaceutical industry. Helén has held various senior positions in Active Biotech and since 2011 she has been responsible for the company's research and development.



"I am proud and glad that in Helén Tuvesson we have an internal candidate who can take responsibility as CEO, ensuring continuity and a controlled handover. Helén has been instrumental in the structural changes made in the company during 2016/2017 and has a solid industry experience. I am convinced that she has the qualities required to shape the company's future strategy and maximize its opportunities," says Mats Arnhög, Chairman of the Board.



"I would also like to thank Tomas Leanderson for his significant contribution to the company's business for a long period. Tomas Leanderson will be at the company's disposal during a transitional period," said Mats Arnhög.



"I am very happy and at the same time humbled for the confidence to lead Active Biotech further. I am well acquainted with the company's projects and its potential and look forward to developing the portfolio further and creating value for the company," says Helén Tuvesson.

Lund June 19, 2017

Active Biotech AB (publ)

For further information, please contact:

Mats Arnhög

Chairman of the Board

Tel +46 8 54503770

Mobil: +46 705 915096

Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/ inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Anyara, cancer immunotherapy, previously in clinical Phase 1-2/3 development in patients with pancreatic-, lung- or renal cancer. Furthermore, commercial activities are conducted for the tasquinimod, paquinimod and SILC projects. Please visit www.activebiotech.com for more information.

Active Biotech AB

(Corp. Reg. No. 556223-9227)

Box 724, SE-220 07 Lund, Sweden

Tel: +46 (0)46 19 20 00

This information is information that Active Biotech AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the contact person set out above, at 15.30 a.m. CET on June 19, 2017.

Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017






This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Globenewswire




 

Breaking News


Kurs- und weitere Informationen zum Thema:

Active Biotech

Aktuelle Diskussionen zum Thema:

Active Biotech - Rebound alter ... (08.05.17)

Aktuelle Nachrichten zum Unternehmen:

Active Biotech AB bricht nach en. (01.08.11)
Active Biotech bricht nach enttäus. (01.08.11)
Evotec und Active Biotech vereinb. (06.06.11)
Evotec und Active Biotech unterze. (11.03.10)

Alle Nachrichten zum Unternehmen

Aktuelle Analysen zu den Unternehmen:

Active Biotech
Weitere Meldungen
 
19.06 Songa Offshore SE : Manda.
19.06 Nets A/S: Final transactions.
19.06 The valuation of Mandatum .
19.06 Helén Tuvesson new CEO o.
19.06 NADL - Announces contract.
19.06 Ad hoc: CropEnergies erhöh.
19.06 Ad hoc: ICHOR Coal N.V.: .
19.06 187,133 Orion Corporation A.
19.06 Ad hoc: Bestandsentwickler .
19.06 Ad hoc: paragon AG beschl.
19.06 Marathon Asset Managemen.
19.06 Ad hoc: Ad-hoc: Preisspann.
19.06 EQS-Adhoc: Conzzeta: Stark.
18.06 EQS-Adhoc: AEVIS VICTOR.
17.06 Ad hoc: Pyrolyx AG: Fremd.
17.06 DBV Technologies Highlights.
16.06 Schrader Cellars Entrusts Co.
16.06 Fortis settlement not declare.
16.06 Ad hoc: Constantin Medien .
16.06 ArcelorMittal led consortium .
16.06 Songa Offshore SE : Manda.
16.06 Nordic Mines AB (publ) and.
16.06 Ad hoc: ADLER Real Estat.
16.06 FDA posts briefing materials.
16.06 Bavarian Nordic Announces .
16.06 Annual General Meeting of .
16.06 Voting Results from Conste.
16.06 Volta Finance Limited : Net .
16.06 Exercise of call options
16.06 Bavarian Nordic Provides Up.


Umfrage
 
Welche Social Networks nutzen Sie meistens?
Facebook
keine
Twitter
Xing
Linked in
Youtube
myspace
Google+
Wikipedia
andere


Stimmen: 23614 , Ergebnis


Kurssuche
Status: nicht eingeloggt

Registrieren | Passwort vergessen?
 
 
Im Bereich Nachrichten:
Nordex SE: Rette sich wer kann?
Experte: Stefan Hofmann, STOCK-WORLD
Kolumnen
Amazon: Was bringt die ...
Robert Sasse, (11:19)
Experte: Robert Sasse,
Mit der richtige Trading-...
RuMaS, (11:06)
Experte: RuMaS,
Hüfners Wochenkommentar ...
Redaktion boerse-frankf., Deutsche Börse AG (10:35)
Experte: Redaktion boerse-frankfurt.de, Deutsche Börse AG
Baader Bond Markets ...
Klaus Stopp, Baader Bank AG (10:23)
Experte: Klaus Stopp, Baader Bank AG
Galencia AG emittiert ...
Sabine Traub, Börse Stuttgart AG (10:15)
Experte: Sabine Traub, Börse Stuttgart AG
Merck & Co. konnte ...
Volker Gelfarth, (10:02)
Experte: Volker Gelfarth,
Nordex und EON – was die ...
Feingold-Research, (09:52)
Experte: Feingold-Research,
Halvers Woche: "Ist die ...
Robert Halver, Baader Bank AG (09:37)
Experte: Robert Halver, Baader Bank AG
DOW: Korrektur intakt!
Admiral Markets, (08:59)
Experte: Admiral Markets,
ThyssenKrupp, Merck und ...
Jürgen Schwenk, Herausgeber Bullenbrief (08:55)
Experte: Jürgen Schwenk, Herausgeber Bullenbrief
Deutsche Reallöhne steigen ...
Markus Fugmann, actior AG (08:43)
Experte: Markus Fugmann, actior AG
Von wegen technischer ...
Bernd Niquet, Autor (24.06.17)
Experte: Bernd Niquet, Autor
Niquet's World
Neues vom Portal
 
Aktien kaufen auf Kredit? Was sind die Vorteile und Nachteile?
Letzte Börsen-Meldung
 
Letzte Börsen-Analyse
 
Top-Klicks News
 
Top-Klicks Analysen